Vaxxirna launches to advance next-gen RNA vaccines
Summary
Vaxxirna has launched as an independent biotech company focused on next-generation RNA vaccines. The company is building on its proprietary viRNA circular RNA platform to address limitations in first-generation linear mRNA vaccines. Its approach aims to improve antigen durability, reduce cold-chain dependence, and make vaccine deployment easier across healthcare settings. The launch creates a new player in the infectious disease vaccine space, but the article does not mention financing, partnerships, or a product release.
Classifications
industries
No industries detected
applications
No applications detected
AskAI Classifications
Labels
No AI classifications detected